Compare EVCM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | PRCT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2021 |
| Metric | EVCM | PRCT |
|---|---|---|
| Price | $9.19 | $19.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 15 |
| Target Price | $11.00 | ★ $22.25 |
| AVG Volume (30 Days) | 103.6K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | 1.71 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $588,907,000.00 | $308,054,000.00 |
| Revenue This Year | $4.16 | $28.32 |
| Revenue Next Year | $4.89 | $20.48 |
| P/E Ratio | $102.33 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $6.21 | $16.67 |
| 52 Week High | $14.41 | $38.11 |
| Indicator | EVCM | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 56.43 |
| Support Level | $8.55 | $17.00 |
| Resistance Level | $10.09 | $19.87 |
| Average True Range (ATR) | 0.44 | 0.99 |
| MACD | -0.00 | 0.23 |
| Stochastic Oscillator | 13.83 | 93.25 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.